person · Reporting owner
VANLANDINGHAM JACOB PH.D
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Health, Inc.ODYY · Entity 8618 | Related Party | October 14, 2022 | October 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Health, Inc.
Report date October 14, 2022 · Filed October 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2032-10-13 | Direct | 2,100,000 |
Reported balance
After 2022-10-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-14 · Grant · Acquired 1,000,000 · Balance 2,100,000 F1: Vesting Schedule 250,000 upon signing; 250,000 upon an IND being approved by the FDA for Phase 2; 250,000 upon a listing on a national exchange (Nasdaq, NYSE); and 250,000 one year from Effective Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting Schedule 250,000 upon signing; 250,000 upon an IND being approved by the FDA for Phase 2; 250,000 upon a listing on a national exchange (Nasdaq, NYSE); and 250,000 one year from Effective Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2022 Filed Oct 19, 2022 21:27 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.32 Strike: $0.32 | $318,000.00 |
DisclosureSEC source: 0001683168-22-006969 · ownership.xml · derivative · entry 1 VANLANDINGHAM JACOB PH.D · CIK 0001794273 · Related Party 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-10-13 F1 · derivative.exercise_date: Vesting Schedule 250,000 upon signing; 250,000 upon an IND being approved by the FDA for Phase 2; 250,000 upon a listing on a national exchange (Nasdaq, NYSE); and 250,000 one year from Effective Date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 16:10 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantODYY common stock $0.001 par value | 1,000,000 | $0.23 | $230,000.00 |
DisclosureSEC source: 0001683168-22-004341 · ownership.xml · nonDerivative · entry 1 VANLANDINGHAM JACOB PH.D · CIK 0001794273 · VP of Drug Development 10b5-1 filing: Not disclosed Ownership: Indirect · By Prevacus, Inc. Disclosed balance after: 9,660,000 Read SEC document |
| May 19, 2022 Filed Jun 8, 2022 17:18 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.30 Strike: $0.30 | $30,000.00 |
DisclosureSEC source: 0001683168-22-004244 · ownership.xml · derivative · entry 1 VANLANDINGHAM JACOB PH.D · CIK 0001794273 · VP of Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,000 Underlying: Common Stock · 100,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: Vesting Schedule: 50% vest on first dosed subject of Phase 2 Trial; 50% on last dosed subject of Phase 2 Trial. Read SEC document |
| March 01, 2021 Filed Apr 9, 2021 17:01 UTC | Odyssey Health, Inc. ODYY · Entity 8618 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $1.18 Strike: $1.18 | $1,180,000.00 |
DisclosureSEC source: 0001683168-21-001306 · ownership.xml · derivative · entry 1 VANLANDINGHAM JACOB PH.D · CIK 0001794273 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: ODYY - Common Stock · 1,000,000 shares Expires 2024-03-01 F1 · derivative.exercise_date: Vesting schedule: 250,000 shares vest on signing of closing documents; 250,000 shares vest on Phase 1a first dosing of human; 250,000 shares vest on Phase 1b first dosing of human; and 250,000 shares vest upon Company being accepted on NASDAQ. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.